|
|
Research on a Novel Sodium AlginateDexamethasone Composite Coating with MultiAldehyde Groups Applied to Extracoporeal Circuits#br# |
1 Heart Center, The Third Central Hospital of Tianjin, Tianjin 300170, China
2 Key Laboratory of Artificial Cells of Tianjin, Tianjin 300170, China |
|
|
Abstract The aim of this work is to prepare a novel composite coating of sodium alginate and dexamethasone. By optimizing the coating mode and conditions, the properties of stability, anticoagulation and controlled release were evaluated. Polyethyleneimine (PEI) was coated on PVC pipelines surface pretreated with acidification, dexamethasone sodium phosphate (DSP) was coated on PEIcoated pipelines (PP) with ionic bond, DSP coated pipelines were created (Group PPD). Pipelines coated OSADXM composite were created by ionic bond (Group PPI) or covalent bond (Group PPC). The control group (Group C) was set as well. The optimum coating condition was obtained by the orthogonal test. By evaluating the properties of different coated pipelines including anticoagulation, platelet adhesion, protein adhesion and release in vitro, the optimum coating mode was determined. DSP can be bound to PVC surface in Group PPD, PPI and PPC. The optimum immobilization quantity of DSP on different groups are (333±075),(163±076),(206±068) μg/cm2. The platelet adhesion (109/L) of Group PPI and PPC (1388±189 and 1913±340) was significantly reduced than that of Group C (4138±320). The protein adhesion (mg/cm2) of Group PPI and PPC (HAS: 2986±1357 and 4667±320, HPF: 3499±352 and 4567±379) was significantly decreased than that of Group PPD (Has: 6873±426, HPF: 7254±790). The release property of Group PPC is superior to that of Group PPI. The coating of OSADXM composite exhibited improved hemocompatibility. Covalently bound DSP can be controlled released.
|
|
|
|
|
[1]Apostolakis EE, Koletsis EN, Baikoussis NG, et al. Strategies to prevent intraoperative lung injury during cardiopulmonary bypass [J]. J Cardiothorac Sury, 2010,11(5):1-9.[2]Suzuki Y, Daitoku K, Minakawa M, et al. Poly2methoxyethylacrylatecoated bypass circuits reduce activation of coagulation system and inflammatory response in congenital cardiac surgery [J]. J Artif Organs, 2008, 11(3): 111-116.
[3]Finne-Wistrand A, Albertsson AC, Kwon OH, et al. Resorbable scaffolds from three different techniques: electrospun fabrics, saltleaching porous films, and smooth flat surfaces[J]. Macromol Biosci, 2008, 8(10): 951-959.
[4]Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass [ J ]. Int J Surg, 2005, 3(2): 129-140.
[5]Sperling C, Houska M, Brynda E, et al. In vitro hemocompatibility of albuminheparin multilayer coatings on polyethersulfone prepared by the layerbylayer technique [J]. J Biomed Mater Resa, 2006,76(4):681-689.
[6]Weber N, Wendel HP, Ziemer G. Hemocompatibility of heparincoated surfaces and the role of selective plasma protein adsorption[J]. Biomaterials, 2002, 23(2): 429-439.
[7]柏淑颖,朱德明,王伟. 涂层技术在体外循环装置中的应用及意义 [J]. 中国体外循环杂志,2009,7(2):124-128.
[8]Larm O, Larsson R, Olsson P. A new nonthrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue[J]. Biomater Med Devices Artif Organs, 1983,11(2-3):161-234.
[9]Andersson LO, Hoffman J,et al. Mechanisms of anticoagulant effects of some sulphated polysaccharides[J]. Thromb Res,1982, 28(6):741-748.
[10]Nishino T, Yokoyama G, Dobashi K, et al. Isolation, purification, and characterization of fucosecontaining sulfated polysaccharides from the brown seaweed Ecklonia kurome and their bloodanticoagulant activities [J]. Carbohydr Res, 1989,
186(1):119-148.
[11]Manju S, Muraleedharan CV. Evaluation of alginate dialdehyde crosslinked gelatin hydrogel as a biodegradable sealant for polyester vascular graft[J]. J Biomed Mater Res B Appl Biomater, 2011, 98(1):139-188.
[12]Bouhadir KH, Lee KY, Alsberg E, et al. Degradation of partially oxidized alginate and its potential application for tissue engineering [J]. Biotechnol Prog,2001,17(5):945-995.
[13]Bron JL, Vonk LA, Smit TH, et al. Engineering alginate for intervertebral disc repair [J]. Mech Behav Biomed Mater. 2011,4(7):1196-1205.
[14]Popa EG, Gomes ME, Reis RL. Cell delivery systems using alginate—carrageenan hydrogel beads and fibers for regenerative medicine applications[J]. Biomacromolecules, 2011, 12(11):3952-3961.
[15]Barnett BP, Arepally A, Stuber M, et al. Synthesis of magnetic resonance-, Xray- and ultrasound visible alginate microcapsules for immunoisolation and noninvasive imaging of cellular therapeutics [J]. Nat Protoc, 2011, 6(8): 1142-1151.
[16]张苑,袁惠燕,吴威,等. 不透X射线栓塞微球的制备及其性质评价[J].北京大学学报(医学版),2009, 41(4):447-451.
[17]Park SJ, Shin S, Koo OJ, et al. Functional improvement of porcine neonatal pancreatic cell clusters via conformal encapsulation using an airdriven encapsulator [J]. Exp Mol Med, 2012, 44(1): 20-25.
[18]Shao Shiying, Gao Yun, Xie Bing, et al. Correction of hyperglycemia in type 1 diabetic models by transplantation of encapsulated insulinproducing cells derived from mouse embryo progenitor [J]. J Endocrinol, 2011, 208(3): 245-255.
[19]高长路,武林枫,刘颖欣,等. 微囊化兔甲状旁腺组织异种移植治疗甲状腺功能低下症的实验研究[J]. 中国普外基础与临床杂志,2006,13(3):256-259.
[20]Weir MD, Xu HH. Human bone marrow stem cellencapsulating calcium phosphate scaffolds for bone repair[J]. Acta Biomater, 2010, 6(10): 4118-4126.
[21]Forster RE, Thürmer F, Wallrapp C. Characterisation of physicomechanical properties and degradation potential of calcium alginate beads for use in embolization [J]. J Mater Sci Mater Med, 2010, 21(7): 2243-2251.
[22]李金友,李彤,高文卿,等. 新型醛基化海藻酸钠抗凝血涂层物制备及性能评价[J]. 中国生物医学工程学报,2012,31(6):918-924.
[23]Checchia PA, Bronicki RA, Costello JM, et al. Steroid use before pediatric cardiac operations using cardiopulmonary bypass:an international survey of 36 centers [ J ]. Pediatr Crit CareMed, 2005, 6(4): 441-444.
[24]Kirklin JK. The postperfusion syndrome: inflammation and the damaging effects of cardiopulmonary bypass[A]. In: Tinker JH(ed): cardiopulmonary bypass: current concept and controversies[M]. Philadelphia: W. B. Saunders, 1989: 131-146.
[25]Kirklin JK. Prospects for understanding and eliminating the deleterious effects of cardiopulmonary bypass [J]. Ann Thorac Surg, 1991, 51 (4): 529-531.
[26]Rep logle RL, Gazzaniga AB, Gross RE. Use of corticosteroids during cardiopulmonary bypass: possible lysosome stabilization[J]. Circulation, 1966, 33 (4 Suppl): 86-92.[27]王琴梅,张亦霞,李卓萍,等. 多醛基海藻酸钠交联剂的制备及性能 [J]. 应用化学, 2010,27(2):155-158.
[28]Yii M, Gourlay T, Fleming J, et al. Evaluation of Carmeda bioactive surface (CBAS), Duraflo and a novel nonspecial proteasemodified surface using a new in vitro model simulating cardiopulmonary bypass[J].Perfusion, 1996, 11(3): 229-240.
[29]Dubois M,Gilles KA,Hamilton JK,et al. Colorimetric method for determination of sugars and related substances [J].Analytical Chemistry, 1956, 28(3): 350-356.
[30]Ishihara K, Fukumoto K, Iwasaki Y, et al. Modification of polysulfone with phospholipid polymer for improvement of the blood compatibility. Part 1. Surface characterization [J].Biomaterials, 1999, 20(17):1545-1551.
|
|
|
|